The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Airlines Hit As UK Quarantine List Grows

Fri, 14th Aug 2020 10:56

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - LOSERS

----------

International Consolidated Airlines, down 6.5%. Shares in the British Airways parent were lower after the UK added France to its 14-day quarantine list. People arriving in the UK after 0400 BST on Saturday will be required to spend 14 days in self-isolation due to rising numbers of coronavirus cases in France. The conditions will also apply to travellers returning to the UK from the Netherlands, Monaco, Malta, Turks & Caicos and Aruba. The move, which applies throughout the UK, comes after Prime Minister Boris Johnson promised to be "absolutely ruthless" in decisions about imposing quarantine restrictions on countries. "The problem for the airlines is that people's desire for a break in the sun may be outweighed by their fear of the logistical challenges of holing up for two weeks when they get back, with decisions on which countries to add to the quarantine list often coming at short notice. This decision will feel particularly painful as it comes at the height of the UK holiday season and the question now becomes just how long the likes of EasyJet, Ryanair and British Airways-owner IAG can continue under these conditions," AJ Bell's Russ Mould commented.

----------

FTSE 250 - WINNERS

----------

Rank Group, up 3.5%. Shares in the gambling company were higher ahead of the reopening of casinos in the UK this weekend, as lockdown restrictions ease further. Under social distancing rules, casinos in the UK will reopen on Saturday for the first time since the lockdown was imposed. Rank Group owns Grosvenor Casinos, the largest UK casino operator with 52 casinos nationwide and Mecca Bingo, the UK's leading bingo operator.

----------

FTSE 250 - LOSERS

----------

easyJet, down 7.5%, Tui, down 5.8%. The travel stocks were dealt a blow by the UK government decision to add France to the quarantine list. "With France being added to the quarantine list for the UK, travel & leisure is under pressure. Shares in IAG, Ryanair, Tui and EasyJet were all sharply lower as the move will force a large swathe of cancellations right at the peak of the summer holiday season for one of the largest markets for UK tourists. Half a million Brits are thought to be in France right now," said Markets.com analyst Neil Wilson. Elsewhere, Irish carrier Ryanair Holdings was down 4.9% and Dart Group, which owns the Jet2 airline, was down 9.5%.

----------

WH Smith, down 5.5%. Shares in the books, magazines and confectionery retailer were also lower as part of the UK's new quarantine travel rules. WH Smith generates a substantial amount of its revenue from stores in airports and train stations. "Related stocks were also hit. WH Smith - purveyor of overpriced sweets and Evian - slipped down the board as a result. Apart from the immediate damage this will do at the height of the school holidays and peak summer season, the quarantine decision also underlines the inherent risk you take in booking a holiday abroad right now, which will do nothing for consumer confidence," Wilson added.

----------

Domino's Pizza, down 5.5%. Citigroup downgraded the pizza delivery chain to Sell from Neutral.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Verona Pharma, up 28%. The pharmaceutical company said the impact of Covid-19 on clinical trials in the first half has been limited, and the company remains on track to start its Phase 3 clinical trials with Ensifentrine for the treatment of chronic obstructive pulmonary disease later in 2020. The company also said it has received a notice from US Food & Drug Administration to proceed with a study of Ensifentrine in patients with Covid-19. The company plans to initiate a randomized, double-blind, placebo-controlled pilot clinical study to evaluate Ensifentrine delivered via pressurized metered-dose inhaler formulation as a treatment for patients hospitalized with Covid-19 at the University of Alabama. The study is expected to start in the third quarter of 2020. Ensifentrine is an investigational inhaled therapy that has been shown to act as both a bronchodilator and an anti-inflammatory agent in one compound.

----------

Bluejay Mining, up 12%. The miner said it completed a final public consultation meeting as part of its attempts to ink an exploitation licence for a project in Greenland. The public consultation for the Dundas ilmenite project was previously hit with delays. Due to Covid-19 affecting consultation meetings, the government of Greenland extended the consultation period from eight to 10 weeks, Dundas said in June. And in July, Bluejay had agreed an offtake deal with a "multinational commodity trading firm" at Dundas increased. The new agreement increased the amount of ilmenite to between 250,000 and 300,000 tonnes per year, extending agreement by three months to October 31.

----------

Quiz, up 8.0%. The fashion retailer said it has secured an increase and extension to its existing loan facilities from lender HSBC. The clothing company's total bank facilities has been doubled to GBP3.5 million from GBP1.8 million, comprising an overdraft facility of GBP2.0 million and a working capital facility of GBP1.5 million. The loans will remain in place until the end of October. There are no financial covenants applicable to the facilities. Quiz, which has been hammered by the Covid-19 lockdown, has GBP5.7 million in cash in addition to the loan facilities.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
7 Mar 2014 09:39

Friday broker round-up UPDATE

AGA Rangemaster: N+1 Singer ups target price from 175p to 192p and maintains a buy recommendation. Aggreko: JP Morgan lowers target price from 1542p to 1536p and maintains a neutral rating. Goldman Sachs increases target price from 1876p to 1950p and keeps a buy recommendation. Numis upgrades to re

Read more
6 Mar 2014 18:02

Verona Pharma Looks To Raise Up To GBP14 Million In Share Placing

LONDON (Alliance News) - Verona Pharma PLC Thursday said it intends to raise up to GBP14 million before expenses in a share placing, subscription, and open offer, which it said it will use to fund further development of its RPL554 drug. The drug development company focuses on medicines to t

Read more
11 Nov 2013 08:50

Monday broker round-up UPDATE

Associated British Foods: Barclays downgrades to equal-weight with a target price of 2100p. Bovis Homes Group: Deutsche Bank moves target price from 1001p to 1008p maintaining a buy recommendation. British Land: Deutsche Bank downgrades to sell with a target price of 520p. British Sky Broadcastin

Read more
25 Oct 2013 08:35

Verona Pharma Says RPL554 Drug Trial Positive

Read more
30 Sep 2013 12:47

Verona Pharma Widens Losses As Treatment Development Continues

Read more
5 Sep 2013 09:37

Verona Pharma Appoints Chroma CEO Bungay As New Part-Time CFO

Read more
5 Sep 2013 08:15

Verona Pharma replaces CFO Lowe with Bungay

Verona Pharma on Thursday said Chief Financial Officer (CFO) Danny Lowe would be replaced by Richard Bungay with immediate effect. Bungay will work part-time at the respiratory treatments specialist at first and Lowe will work with him for an interim period to make sure there is a smooth handover.

Read more
23 Jul 2013 16:21

SABMilller Chairman sells over 11m pounds in shares

Graham Mackay, the Chairman of SABMiller who is currently on a medical leave of absence due to a brain tumour, has sold over 11m pounds-worth of shares in the company. Mackay sold a total of 350,000 shares between July 16-18th through three separate transactions, the firm revealed on Tuesday. He so

Read more
26 Apr 2013 15:09

Advanced Oncotherapy CEO makes triple purchase

The Chief Executive of Advanced Oncotherapy, a provider of new technology for innovative and patient-focused cancer treatments, has this week purchased three lots of shares in the group, taking his stake to just under 69.4m shares. On Thursday Sinclair purchased one round of 8.075m shares at 1.59p

Read more
10 Apr 2013 16:27

AZ Electronic Materials directors try to minimize damage

John Whybrow, the Chairman of AZ Electronic Materials, which on Tuesday tanked after it issued a warning on full year revenue, has shown his faith in the chemicals company by enlarging his shareholding. Whybrow acquired 40,000 shares at 254p each for a total trade value of £101,600, taking his sta

Read more
4 Sep 2012 08:58

Small caps round-up: Verona, Image Scan, Avia

Respiratory diseases specialist Verona Pharma has hailed a positive outcome of a clinical trial of its lead drug candidate, the snappily-named RPL554. The data showed that a single dose of RPL554 in spray form administered to patients with chronic obstructive pulmonary disease (COPD) produced a ra

Read more
28 Aug 2012 14:43

Small caps round-up: Transense Tech, Hightex, Verona Pharma

Transense Technologies, which provides sensor systems for the transportation and industrial markets, has reported that its trading division, Translogik, has received an initial order for its iTrack Tyre Temperature and Pressure Monitoring Systems for mining and off-the-road vehicles from its Indones

Read more
9 Jul 2012 10:25

Small caps round-up: Lighthouse, Verona Pharma, Manroy...

Shares in Lighthouse Group, the financial advice and wealth management group, plunged on Monday after the company proposed to cancel its listing on AIM. The group must receive approval from shareholders representing at least three-quarters of the company's shares for the cancellation to be approved.

Read more
26 Nov 2010 15:56

Small caps round-up: Verona Pharma, PHSC, Sterling Green

Verona Pharma, respiratory diseases treatment developer, is initiating a new higher dose trial of its lead drug, RPL554, in patients with asthma, after receiving the go-ahead from the Dutch authorities. The company also announced that it has completed proof of concept trials on delivering RPL554 vi

Read more
28 Jun 2010 07:33

Verona Pharma In Talks With Licensees For RPL554 Cough Project

LONDON (Dow Jones)--Verona Pharma PLC (VRP.LN), an AIM quoted drug discovery company, said Monday licensing discussions continue to advance with potential licensees for its RPL554 cough project and it plans three clinical trials to add value to licensing package for RPL554. MAIN FACTS: -Has

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.